Overview
CADL market data
Price History
CADL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.74 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.33 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -15,156.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.35 – $11.36 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $769.3M · P/B 5.97 · P/S 6,204.33.
Company News
HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price TargetBenzinga · Aug 13, 2026, 4:06 PM
Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) EstimateBenzinga · Aug 13, 2026, 12:47 PM
8-K filing — Candel Therapeutics, Inc. (CADL)SEC EDGAR · Aug 13, 2026, 12:15 PM
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22Benzinga · Jul 13, 2026, 9:53 AM
Candel Therapeutics Starts Pivotal Phase 3 AURORA Study Of Aglatimagene Besadenovec Plus Valacyclovir In Combination With Continued Pembrolizumab In Participants With Metastatic Non-Squamous Non-Small Cell Lung CancerBenzinga · Jun 30, 2026, 12:20 PM
Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate CancerBenzinga · Jun 2, 2026, 12:19 PM
Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual MeetingBenzinga · May 15, 2026, 8:07 PM